Polyvalent Interactions in Biological Systems — Mammen, Choi, Whitesides 1998

Citation: Mammen, M., Choi, S.-K., & Whitesides, G.M. (1998). Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. Angew. Chem. Int. Ed., 37, 2754-2794.

Authors: Harvard University — Whitesides group.

What Polyvalency Means

A polyvalent interaction is the simultaneous binding of multiple ligands on one entity to multiple receptors on another. It occurs throughout biology — influenza HA × sialic acid, antibodies × antigens, selectins × sLeX in inflammation, transcription factor oligomers × DNA repeat elements.

Core Thermodynamic Logic

When N ligands bind N receptors simultaneously:

• The translational/rotational entropy penalty (ΔG^s) is paid once total rather than N times.
• Each additional ligand contributes its intrinsic binding energy (ΔG^i) at much lower entropic cost than if it bound independently.
• Result: collective affinity can be orders of magnitude higher than expected from monovalent affinity alone.

Key parameter introduced: β (polyvalent enhancement) β = K_poly / K_mono — how much better the polyvalent agent is vs the monovalent equivalent.

Two Main Mechanisms of Polyvalent Inhibition

1. Statistical rebinding: After one ligand dissociates, the tethered cognate ligand is at high effective local concentration and rebinds before the whole complex can dissociate. Dramatically slows off-rate.
2. Steric stabilization: Polymer chains on polyvalent inhibitors sterically block access to binding sites on target surfaces (e.g., influenza virus blocked from binding sialic acid on cells).

Influenza as the Paradigm Case

• HA trimers: 600-1200 per virion, spacing ~10-20 nm
• Sialic acid: 50-200 per 100 nm² on target cells
• Polymeric sialic acid inhibitors achieve IC₅₀ values 10⁶ × lower than monovalent sialic acid
• Both statistical rebinding and steric shielding contribute — separable by chain length experiments

Biological Examples

• Virus adhesion: influenza, HIV, RSV — all use polyvalent surface attachment
• Neutrophil rolling: selectins × sLeX; kinetics controlled by number of simultaneous contacts
• Antibody clearing: IgM (10 binding sites) dramatically more effective than IgG (2 sites) for clearance by macrophage Fc receptors
• Transcription factor oligomers: rate ∝ [TF]^N where N = valency — ultra-sharp concentration response

Design Principles for Synthetic Polyvalent Ligands

1. Ligand spacing must match receptor spacing on target — use flexible linkers of varying length to scan
2. Optimal linker length peaks sharply — too short or too long both reduce potency
3. Flexible polymers (PEG) sample a hemisphere of radius = rms length: C_eff = 1000/(N_A × 2/3πr³)
4. Rigidity matters: stiffer linkers give sharper specificity but narrower optimum
5. Polymer backbone itself can contribute steric effects independent of the ligands

Relevance to STRC Therapeutic Design

If designing a small-molecule or peptide therapeutic to stabilize the stereocilia tectorial membrane attachment zone where STRC operates, polyvalent display on a scaffold could be the difference between a weak binder and a clinical-grade compound. The Mammen framework gives the quantitative basis for predicting how much affinity gain is achievable and how to scan for the right linker length.

Connections

• [source] Polyvalent (self) (self)
• [about] Polyvalent Binding and Avidity
• [about] Multivalent Ligand Design Principles
• [supports] Polymer-Linked Ligand Dimer Strategy
• [see-also] Intrinsic Binding Energy and Connection Gibbs Energy
• [see-also] STRC Gene Therapy sphere